Senores Pharmaceuticals Ltd. is an emerging player in the Indian pharmaceutical sector, specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), formulations, and critical care products. The company has recently gained attention for its strategic acquisitions, including 14 Abbreviated New Drug Applications (ANDAs) from Dr. Reddy’s Laboratories, which are expected to bolster its presence in regulated markets. ETPharma.com
Projected Share Price Targets
Based on expert analyses and market trends, here are the projected share price targets for Senores Pharmaceuticals over the next two decades:
| Year | Minimum Price (₹) | Maximum Price (₹) |
|---|---|---|
| 2025 | ₹439.6 | ₹950 |
| 2026 | ₹788.6 | ₹1,300 |
| 2030 | ₹1,050 | ₹3,200 |
| 2040 | ₹2,011 | ₹6,700 |
| 2050 | ₹4,667 | ₹5,244 |
Note: These projections are based on historical data, market trends, and company performance. Actual future prices may vary.
Factors Influencing Share Price
Several factors contribute to the projected growth in Senores Pharmaceuticals’ share price:
- Strategic Acquisitions: The acquisition of ANDAs from Dr. Reddy’s Laboratories enhances the company’s product portfolio and market access.ETPharma.com
- Regulatory Approvals: Securing approvals from global regulatory bodies such as the US FDA and EU authorities for new products can significantly boost market presence and investor confidence.LDCC Bank
- Research and Development: Continuous investment in R&D to develop innovative and complex medicines positions the company for sustained growth.Share Price Target+1Share Price Target+1
- Market Expansion: Efforts to penetrate emerging markets and strengthen exports contribute to revenue diversification and stability.
Risks and Considerations
Investors should be aware of potential risks:
- Regulatory Challenges: Delays or issues in obtaining necessary approvals can impact product launches and revenue streams.
- Market Competition: Intense competition in the pharmaceutical industry may affect market share and profitability.
- Operational Risks: Dependence on third-party manufacturers and suppliers introduces risks related to production and supply chain disruptions.
What is Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd. is an Indian company in Ahmedabad established in 2017. It makes and develops medicines, mainly for markets like the United States, Canada, and the United Kingdom. The company works in several medical areas and produces different types of medicines. It also works with other companies to source certain products that meet the specific needs of its customers and marketing partners. The company uses its facility in Atlanta to offer services such as Contract Development and Manufacturing products.
Senores IPO Details
| IPO Date | December 20, 2024 to December 24, 2024 |
| Listing Date | — |
| Face Value | ₹10 per share |
| Price Band | ₹372 to ₹391 per share |
| Minimum Investment | ₹14,136 |
| Lot Size | 38 Shares |
| Total Issue Size | 1,48,87,723 shares |
| Fresh Issue | 1,27,87,723 shares |
| Offer for Sale | 21,00,000 shares of ₹10 |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 3,32,65,865 shares |
| Share Holding Post Issue | 4,60,53,588 shares |
share price Target Tomorrow
This company has a strong presence in growing markets, operating in 43 countries. The company has formed partnerships in well-regulated markets such as the US, Canada, and the UK, working with both global and Indian pharmaceutical companies. With time passing its finances improved very well, in 2023, its profit was just 8.43 Cr whereas in 2024 it became 32.71. The company’s fundamentals are very strong which supports it for further growth.
| Day | Minimum Price (Rs) | Maximum Price (Rs) |
| Tomorrow | -48 | +89 |
Senores share price Target 2025
The company does business with the US, Canada, and the UK through agreements with other pharmaceutical companies for marketing and distribution. It has launched a range of products in key areas like antifungals, antibiotics, antibacterial, and blood-related treatments. The company is well-established in hospitals across India, working with distributors and directly with hospitals too. As the company doing well, its stock will do the same in the stock market. In 2025, its share price target would be ₹825, as per our analysis.
By our prediction, its share price would be between ₹435 to ₹825 in 2025.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 435 | 825 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 435 | 597 |
| February | 492 | 644 |
| March | 516 | 665 |
| April | 440 | 626 |
| May | 490 | 647 |
| June | 524 | 678 |
| July | 533 | 690 |
| August | 557 | 721 |
| September | 590 | 740 |
| October | 624 | 774 |
| November | 674 | 800 |
| December | 722 | 825 |
Senores share price Target 2026
It develops and manufactures a variety of pharmaceutical products mainly for regulated markets like the US, Canada, and the UK. The company has launched a range of products and established strong partnerships with distributors and hospitals across India. Also, it operates three dedicated R&D facilities in India and the US and serves 43 countries in emerging markets, manufacturing critical care injectables and active pharmaceutical ingredients. The company doing great business in India as well as internationally. In 2026, its share price target would be ₹1180, as per our analysis.
By our prediction, its share price would be between ₹722 to ₹1180 in 2026.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 722 | 1180 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 722 | 857 |
| February | 755 | 870 |
| March | 774 | 889 |
| April | 791 | 920 |
| May | 800 | 941 |
| June | 823 | 958 |
| July | 845 | 974 |
| August | 874 | 1000 |
| September | 921 | 1041 |
| October | 954 | 1088 |
| November | 980 | 1121 |
| December | 1022 | 1180 |
Share Price Target 2027
In 2027, its share price target would be ₹1538, as per our analysis.
By our prediction, its share price would be between ₹1022 to ₹1538 in 2027.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2027 | 1022 | 1538 |
Share Price Target 2028
In 2028, its share price target would be ₹1184, as per our analysis.
By our prediction, its share price would be between ₹1511 to ₹1184 in 2028.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2028 | 1511 | 1184 |
Share Price Target 2029
In 2029, its share price target would be ₹2221, as per our analysis.
By our prediction, its share price would be between ₹1860 to ₹2221 in 2029.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2029 | 1860 | 2221 |
Senores share price Target 2030
The company uses data, research, and experienced management to find unique and less common molecules for new products in both regulated and emerging markets. The company focuses on developing high-quality, complex medicines. Its strong R&D efforts have led to a wide range of products in different forms and medical areas. It has partnerships with both foreign and Indian pharmaceutical companies in markets like the US, Canada, and the UK. It had a strong presence in the global market, making it an attractive company for investors. In 2030, its share price target would be ₹2554, as per our analysis.
Conclusion
Senores Pharmaceuticals Ltd. presents a promising investment opportunity for long-term investors, given its strategic acquisitions, focus on R&D, and efforts to expand in global markets. While the projected share price targets indicate substantial growth, it’s essential for investors to conduct thorough research and consider potential risks before making investment decisions.
Disclaimer: The information provided is based on available data and projections. Investors should consult financial advisors and conduct their own research before making investment decisions.